VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

FNVHO - US Oncology, Fairfax

Charleston Cancer Center, Charleston

Georgia Cancer Specialists, Marietta

Emory University Cancer Institute, Winship Cancer Institute, Atlanta

Florida Cancer Specialists, Fort Myers

Mid Ohio Oncology/Hematology Inc., Columbus

Midwest Cancer Research Group, Skokie

Rush University Medical Center, Chicago

Oncology/Henmatology Associates of Kansas City, Kansas City

Cancer Center of Kansas, Wichita

MD Anderson Cancer Center, Houston

University of Utah, Huntsman Cancer Institute, Salt Lake City

UCLA School of Medicine, Los Angeles